v3.26.1
Additional Information to the Items of Profit or Loss (Tables)
 12 Months Ended
Dec. 31, 2025
Additional Information to the Items of Profit or Loss [Abstract]  
Schedule of Additional Information to the Items of Profit or Loss
     Year ended December 31, 
     2025   2024   2023
a. Research and development expenses:        
  Wages and related expenses  $329   $390   $392
  Share-based payment   85    45   34
  Regulatory, professional and other expenses   980    681   719
  Research and preclinical studies   364    211   101
  Clinical studies   266    276   254
  Chemistry and formulations   73    104   141
             
      2,097    1,707   1,641
             
b. Sales and marketing expenses:          
  Advertising  $155   $367   $576
  Amazon fees   331    495   1,042
  Amortization   194    366   486
  Storage and shipping   112    167   145
  Management fees   120    120   235
             
      912    1,515   2,484
c. General and administrative expenses:          
  Wages and related expenses   458    507   415
  Share-based payment   1,103    419   68
  Professional and directors’ fees   2,823    3,009   2,594
  Deemed issuance listing expenses   1,410    
-
  
-
  Business development expenses   89    108   86
  Regulatory expenses   222    158   202
  Office maintenance, rent and other expenses   152    128   110
  Investor relations and business expenses   114    197   369
             
      6,371    4,526   3,844
d. Other income, net:          
  Loss from sale of property and equipment   
-
    17  
-
  Gain on settlement of legal dispute   (464)   
-
  
-
  Other income   (26)   
-
  
-
  Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 24g)   
-
    (1,287) 
-
      (490)   (1,270) 
-
             
e. Finance income:          
  Net change in fair value of financial liabilities designated at fair value through profit or loss   (1)   (191)  (2,205)
  Finance income due to cancellation of warrant liability   (1,568)   
-
  
-
  Finance income due to revaluation of convertible debentures   (422)   
-
  
-
  Interest from loans to related parties and deposits   (207)   (421) 
-
  Exchange rate differences   (80)   
-
   (14)
             
      (2,278)   (612)  (2,219)
f. Finance expenses:          
  Impairment of loan (see note 8c)   5,973    
-
  
-
  Issuance expenses   410    
-
  
-
  Exchange rate differences   14    18  
-
  Losses from remeasurement of investment in financial assets   1,791    305   1,046
  Finance expense in respect of leases   5    8   9
  Finance expenses from interest and commissions   6    22  
-
             
     $8,199   $353   $1,055